ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves
ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves near-field focus and image quality, according to the Bothell, WA, vendor. ATL has also received PMAs for breast imaging applications with its Ultramark 9 HDI and HDI 3000 systems.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.